PARIS—The eyewear giant that owns Ray-Ban, LensCrafters and dozens of other brands is in turmoil as a public fight broke out between top executives over control of the company, just six months after they created it in a merger of equals.
Shares of EssilorLuxottica SA, the world’s leading eyewear company with more than €16 billion in annual revenue, fell 6.6% on Thursday in Paris after a top executive, the Italian billionaire Leonardo Del Vecchio, accused other executives of violating the pact that created...
I hope they can see their way clear to an amiable settlement.
Another brand goes belly up, no surprise when you can buy the same quality product far cheaper with free shipping online!
Мы обобщили эту новость, чтобы вы могли ее быстро прочитать.Если новость вам интересна, вы можете прочитать полный текст здесь Прочитайте больше:
Россия Последние новости, Россия Последние новости
Similar News:Вы также можете прочитать подобные новости, которые мы собрали из других источников новостей
How vision plans rig the eyewear market while keeping consumers in the dark'People tend to think of the vision plans offered by employers as being like any other health insurance. They’re not.' Davidlaz is out with his newest column on how the eyewear industry 'is characterized by consolidation, self-interest and price-fixing.' Previously, he's asked: Just how badly are we being ripped off on eyewear? The answer, from those with first-hand experience: a lot. Davidlaz My doctors have been super awesome about writing all my referrals and stuff for eye doctors in a way that'll get it covered by my regular insurance, but even after ther visit, even the most basic frames and scratch resistant lenses are far above what my 'vision coverage' covers. Davidlaz Truly
Источник: latimes - 🏆 11. / 82 Прочитайте больше »
BioScrip's stock soars after merger deal with Option Care, owned by Walgreens and Madison DearbornShares of BioScrip Inc. soared 32% toward a 4-year high in premarket trade Friday, after the company announced a deal to merge with privately held Option Care Enterprises Inc., a provider of home and alternate treatment site infusion therapy services owned by funds affiliated with Walgreens Boots Alliance Inc. and private-equity firm Madison Dearborn Partners LLC (MDP). BioScrip's stock is halted for news until 7:30 a.m. Eastern. Under terms of the agreement, BioScrip will issue new shares to Option Care's shareholder and Walgreens and MDP will own about 80% of the combined publicly traded company. BioScrip's market capitalization was about $446.9 million as of Thursday's close. "This is a compelling and complementary fit of two leading players in the U.S. infusion market," said BioScrip Chief Executive Daniel Greenleaf. "Together, we will be able to provide a diverse set of life-improving and cost-effective services to more patients across the United States." BioScrip's stock has rallied 31% over the past 12 months, while the SPDR Health Care Select Sector ETF has gained 6.9% and the Dow Jones Industrial Average has tacked on 3.4%.
Источник: MarketWatch - 🏆 3. / 97 Прочитайте больше »
FIS and Worldpay agree on a $43bn mergerThe race to create a global payments giant is shifting up a gear
Источник: TheEconomist - 🏆 6. / 92 Прочитайте больше »